Hemispherx Biopharma's Ampligen Cited at Barcelona Vaccine & Active Immunotherapeutics Forum 2011

Hemispherx Biopharma, Inc. HEB today announced that Ampligen® will be featured in a discussion of "promising new discoveries that will direct step changes in efficacy of next generation cancer immunotherapies" in a round table discussion of Active Immunotherapy held at the Fira Palace in Barcelona May 13, 2011. Dr. Christopher F Nicodemus, a consultant to Hemispherx, was invited to highlight findings from his recently published work with the compound and the work of collaborators.